drugset / Trial / NCT04444271

Mesenchymal Stem Cell Infusion for COVID-19 Infection

NCT04444271

Phase 2 Unknown 20 enrolled Dr. Zaineb Akram
RandomizedParallel-groupOpen-labelTreatment

Summary

Since the outbreak of coronavirusdisease2019(COVID-19), many researchers in China have carried out/published clinical trials on treatment based on Western medicine, traditional Chinese medicine or a combination of the two. Trials on treatment modalities have mainly used antivirals, interferon, glucocorticoids in addition to traditional Chinese medicine. There are also clinical trials exploring hydroxyquinoline/chloroquine sulphate, immunoglobulins, Vitamin-C, washed microbiota, nebulized interferon, teicoplanin as well as Mesenchymal stem cells. However, most of these trials were small (median sample size 100) and the bulk of potential therapeutic strategies remain in the experimental phase and currently there is no effective specific antiviral with high-level evidence.The aim of this study is assess the efficacy of MSCs as an add-on therapy to standard supportive treatment for patients with moderate/severe COVID-19.

Timeline

Start
2020-05-01
Primary completion
2020-08-30
Completion
2020-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 2e+06 cells/kg Intravenous

Indications